Biocon Limited announced its results for the quarter and financial year ended March 2023. The drugmaker has reported a 31.3% increase (after exceptional items) in its profit for the fourth quarter to Rs 313.20 crore.
Consolidated revenues increased 59% year-on-year to Rs 3,929 crore in Q4FY23. The company stated in its filing that the revenue for the quarter includes a Rs 109 crore gain on stake dilution in Bicara.
During the quarter under review, EBITDA increased 75% to Rs 1,152 crore, representing an EBITDA margin of 29% versus 27% in the same period last year.
Consolidated Revenues increased 38% y-o-y to Rs 11,550 crore in FY23. The revenue for the year includes a Rs 217 crore gain on stake dilution in Bicara as a result of its fund raise during the year.
Net Profit for the year, after exceptional items came in at Rs 463 crore, down by 29% y-o-y against Rs 648 crore in the previous corresponding year.
EBITDA was up 32% year on year at Rs 2,888 crore, with an EBITDA margin of 25%.
At around 11.40 AM, Biocon was trading 2.60% higher at Rs 248.45, against the previous close of Rs 242.15 on NSE. The counter touched an intraday high of Rs 260.60 so far in today’s trade.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.